The landscape of dementia prognosis has evolved considerably with the advent of refined biomarkers, including amyloid PET scans, tau imaging, and blood-dependent tests that could detect Alzheimer's pathology decades just before signs or symptoms arise. While these technological improvements characterize remarkable progress in knowing neurodegenerat